{"slideshow_credits": null, "snippet": "A new pill to treat the virus raises difficult questions about fair pricing in the United States and in developing countries around the world.", "abstract": "Editorial submits that new hepatitis C drug Sovaldi raises difficult questions about fair pricing in both United States and rest of world; says drug, which costs $84,000 for 12 week course in US, much higher than proposed price in India, may unduly burden Medicare, Medicaid and taxpayers; urges policy makers to search for ways to lower drug's cost.", "section_name": "Opinion", "print_page": "10", "document_type": "article", "byline": {"person": [], "organization": "THE EDITORIAL BOARD", "original": "By THE EDITORIAL BOARD", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/03/16/opinion/sunday/how-much-should-hepatitis-c-treatment-cost.html", "lead_paragraph": "A new pill to treat the virus raises difficult questions about fair pricing in the United States and in developing countries around the world.", "headline": {"main": "How Much Should Hepatitis C Treatment Cost?", "print_headline": "How Much Should Hepatitis C Treatment Cost?", "content_kicker": "Editorial", "kicker": "Editorial"}, "_id": "53249c2c38f0d86e6417380c", "word_count": "488", "multimedia": [], "pub_date": "2014-03-16T00:00:00Z", "source": "The New York Times", "news_desk": "Editorial", "keywords": [{"value": "Prices (Fares, Fees and Rates)", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Third World and Developing Countries", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Gilead Sciences Inc", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Editorials", "name": "subject", "is_major": "Y", "rank": "6"}, {"value": "Hepatitis", "name": "subject", "is_major": "Y", "rank": "3"}], "blog": [], "subsection_name": "Sunday Review", "type_of_material": "Editorial"}